# Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy

> **NCT02289924** · — · COMPLETED · sponsor: **Bayer** · enrollment: 912 (actual)

## Conditions studied

- Wet Macular Degeneration

## Interventions

- **DRUG:** Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT02289924
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-09
- **Primary completion:** 2019-03-28
- **Final completion:** 2019-07-08
- **Target enrollment:** 912 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02289924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02289924, "Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02289924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*